Contemporary Antiplatelet Therapy and Clinical Outcomes of Japanese Patients With Acute Myocardial Infarction 　- Results From the Prospective Japan Acute Myocardial Infarction Registry (JAMIR).

CONCLUSIONS: The present real-world database of the JAMIR demonstrated that the potent P2Y12-inhibitor prasugrel showed comparable rates of 1-year ischemic events to clopidogrel, but the risk of bleeding was lower with prasugrel than with clopidogrel. PMID: 31204353 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31204353?dopt=Abstract

Source: Circulation Journal - June 13, 2019 Category: Cardiology Authors: Yasuda S, Honda S, Takegami M, Nishihira K, Kojima S, Asaumi Y, Suzuki M, Kosuge M, Takahashi J, Sakata Y, Takayama M, Sumiyoshi T, Ogawa H, Kimura K, JAMIR Investigators Tags: Circ J Source Type: research

Contemporary Antiplatelet Therapy and Clinical Outcomes of Japanese Patients With Acute Myocardial Infarction - Results From the Prospective Japan Acute Myocardial Infarction Registry (JAMIR).

Contemporary Antiplatelet Therapy and Clinical Outcomes of Japanese Patients With Acute Myocardial Infarction 　- Results From the Prospective Japan Acute Myocardial Infarction Registry (JAMIR).